Virchow Medical Raises $4M Seed for Biopsy Stewardship
Virchow Medical, a La Jolla-based developer of devices that capture dislodged tumor cells from biopsy procedures, has raised $4M in seed funding led by Cerberus Ventures. The company creates liquid companion specimens for molecular testing in precision oncology, addressing tissue exhaustion in solid tumor patients. The capital will advance the Virchow Vault biorepository and expand pilot programs in hospitals.
Biopsy Innovations Draw 2026 Funding
The round closes amid rising investment in biopsy technologies. Exact Imaging raised $10M in February 2026 to boost prostate biopsy adoption, while Becton Dickinson gained FDA clearance for its EnCor EnCompass system in January. Virchow's Crow’s Nest system differentiates by recovering wasted cells post-procedure for additional testing, complementing primary biopsy tools from incumbents.
Tissue Shortages Limit Precision Oncology
Precision oncology relies on sufficient tumor tissue for NGS and multi-omic tests, yet biopsies often yield inadequate samples leading to repeat procedures. Up to 30% of biopsies result in quantity not sufficient (QNS) verdicts, per clinical studies at six U.S. institutions. Current devices from Hologic and BD focus on core sample acquisition but discard dislodged viable cells in needles.
Crow’s Nest Recovers Wasted Tumor Cells
Virchow's FDA-registered Crow’s Nest Biopsy Catchment System attaches to used core needles to harvest dislodged tumor cells as fresh liquid specimens. These enable RNA testing, organoid creation, and serial molecular assays without extra biopsies. Unlike vacuum-assisted systems from incumbents, it works with standard procedures to maximize yield from a single pass. In pilots at Portneuf Medical Center and Bingham Memorial Hospital, it demonstrated clinical concordance with solid tissue samples.
As Alexander Arrow, CEO noted:
“It’s the best way to counteract tissue insufficiency… help an enormous number of cancer patients.”
Cerberus Backs Data-Driven Bio Platform
Cerberus Ventures led the round with participation from five physician users; Managing Director Chenny Zhang joined the board. The firm's ex-In-Q-Tel team targets scalable bio platforms for healthcare impact, as seen in prior biotech bets like Ansa Biotechnologies. This investment signals Virchow's positioning as precision oncology data infrastructure amid AI advancements in cancer care.
Chenny Zhang of Cerberus Ventures noted:
“We see Virchow not just as a platform to improve cancer patient outcomes, but also as a differentiated data provider that can help accelerate AI benefits…”
$2.48B Biopsy Market Grows Steadily
The global biopsy devices market stands at $2.48B in 2026, projected to reach $3.74B by 2034 at 5.27% CAGR. Precision oncology expands faster at $146B in 2026. Trends like NGS adoption and value-based care drive demand for tissue stewardship solutions like Virchow's, reducing repeat biopsies and enabling biomarker therapies. Incumbents dominate core devices, leaving post-procedure recovery underserved.
Pathology Expertise Drives IP Innovation
Co-founder Wilfrido Mojica, MD, Chief of Pathology at Niagara Falls Memorial and inventor of Crow’s Nest, brings 23 years optimizing biopsy specimens. CEO Alexander Arrow, Harvard MD and ex-CFO at public medtech firms, served on the board of Paragonix Technologies during its $477M acquisition by Getinge in 2024. Their blend of clinical invention and commercial scaling positions Virchow for hospital adoption.
Pilots Fuel National Hospital Rollout
Funds support Virchow Vault rollout and pilots beyond early sites like Portneuf in the Pacific Northwest. Recent partnerships with PreciseMDX for secure biorepository software and Diagnostic Medicine Consortium for AI analytics signal ecosystem integration. A new U.S. patent strengthens IP as the team eyes broader precision oncology access.